Analysts Set BioNTech SE (NASDAQ:BNTX) PT at $111.70

BioNTech SE (NASDAQ:BNTX) has been assigned a consensus rating of “Hold” from the ten analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $111.70.

A number of analysts have weighed in on BNTX shares. Evercore ISI assumed coverage on BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price target for the company. BMO Capital Markets reduced their price objective on BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $113.00 target price on shares of BioNTech in a research report on Wednesday, June 26th. Finally, TD Cowen upped their price objective on shares of BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th.

BioNTech Trading Up 0.8 %

Shares of NASDAQ BNTX opened at $86.61 on Thursday. The stock’s 50 day simple moving average is $89.20 and its 200 day simple moving average is $91.25. The company has a current ratio of 11.38, a quick ratio of 11.16 and a debt-to-equity ratio of 0.01. The company has a market cap of $20.59 billion, a price-to-earnings ratio of 173.22 and a beta of 0.23. BioNTech has a 12-month low of $78.02 and a 12-month high of $125.83.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The firm had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Equities research analysts expect that BioNTech will post -2 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. lifted its stake in shares of BioNTech by 1.0% during the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock valued at $917,056,000 after buying an additional 86,343 shares in the last quarter. Primecap Management Co. CA boosted its position in BioNTech by 2.8% during the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after buying an additional 131,490 shares during the period. Harding Loevner LP purchased a new stake in BioNTech during the 4th quarter valued at $410,984,000. Flossbach Von Storch AG boosted its position in BioNTech by 1.0% during the 4th quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock valued at $374,526,000 after buying an additional 35,445 shares during the period. Finally, Capital World Investors boosted its position in BioNTech by 0.5% during the 1st quarter. Capital World Investors now owns 943,116 shares of the company’s stock valued at $87,002,000 after buying an additional 4,369 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.